Prader-Willi Syndrome Study


The purpose of the study is to look at the safety, tolerability, and effectiveness of NNZ-2591 in the treatment of children.

Info For Caregivers

You will be responsible for ensuring that the participant attends the study visits to meet with your study doctor and other study staff…


This clinical study is sponsored by Neuren Pharmaceuticals, a biopharmaceutical company headquartered in Melbourne, Australia…

Does someone you know have Prader-Willi syndrome?

Please email to see if they may be eligible to participate in a research study for a new medication open to children and adolescents aged 4-12 years.

Prader-Willi syndrome is a genetically determined neurological disorder, characterized by intellectual disability, growth hormone deficiency, and hyperphagia (as well as other related conditions, i.e. obesity).

This is a spectrum disorder which means not all people display the same behaviors and symptoms.

People with Prader-Willi syndrome need continuous care and are unable to live independently.

There is currently no treatment for Prader-Willi syndrome.